Nearly six years ago, we joined the #FlagshipFounded ecosystem, paving the way for Flagship Pioneering’s #AI portfolio and kickstarting the #GenerativeBiology revolution. In a recent article for Genetic Engineering & Biotechnology News, senior business editor Alex Philippidis discusses Flagship’s latest fundraising round and what it means for startups in the life sciences, sustainability and AI space. Check it out here: https://lnkd.in/evnbfpX9 #ProteinEngineering I #MachineLearning
Generate:Biomedicines
Biotechnology Research
Somerville, Massachusetts 26,578 followers
Pioneering generative biology to create breakthrough therapeutics.
About us
Pioneering generative biology to create breakthrough therapeutics.
- Website
-
https://generatebiomedicines.com/
External link for Generate:Biomedicines
- Industry
- Biotechnology Research
- Company size
- 201-500 employees
- Headquarters
- Somerville, Massachusetts
- Type
- Privately Held
Locations
-
Primary
101 South Street
Suite 900
Somerville, Massachusetts 02143, US
-
4 Corporate Dr.
Andover, Massachusetts 01810, US
Employees at Generate:Biomedicines
Updates
-
What does it take to build an AI-driven biotech in 2024? Our CEO Michael Nally will share his insight into this very topic as part of a panel discussion at Decoding Bio’s second annual AI x Bio Summit at the NYSE on July 25. Convening industry leaders working at the intersection of computation and life sciences, this panel will explore company building strategies, emerging technologies, stakeholder engagement, and more. Mike will be joined by panelists Nabiha Saklayen of Cellino and Sajith Wickramasekara of Benchling, with Bigyan Bista of Enveda Biosciences moderating the discussion. #GenerativeAI | #UnapologeticallyScientific
-
What can’t AI do? Kyle LaHucik at Endpoints News sets out to answer this by exploring how #AI is revolutionizing biotech with insights from Noubar Afeyan, CEO and founder of Flagship Pioneering and our chairman and co-founder. “Multiple Flagship companies are doing work in AI, most notably with Generate:Biomedicines, which has raised more than $700 million to create new proteins using artificial intelligence. It has a broad pipeline across immunology, infectious disease, and oncology,” Afeyan highlighted. #TeamGenerate is harnessing AI to program biology, transforming how medicines are created. Together, we’re targeting humanity’s most intractable diseases with unprecedented precision and speed. Discover more about how AI is driving the future of biotech. https://lnkd.in/dx759Vt9 #GenerativeBiology | #NowWeCan | #FlagshipFounded
I spoke with Flagship Pioneering CEO Noubar Afeyan about the new $3.6 billion pool of capital that the life sciences incubator and investor has to deploy into about 25 companies. We spoke about tackling uncertainties (and can that model be viewed through an efficiency lens?), machine learning's spread, creating the "next-next' iteration of ADCs and radiopharmaceuticals, and more. “The field is dividing up into almost two buckets: people who make bets on very late-stage assets, either as the basis of a startup, knowing that if something hits, then the pharma companies may buy them or the public market would be interested in them,” he told Endpoints News. “Then [there’s the] people who have the resources and the patience to be able to develop entirely new capabilities and see them through, which involves a lot of financing and a lot of partnering.” #flagshippioneering #venturecapital #biotech #lifesciences #incubator #pharma #drugdevelopment
CEO Noubar Afeyan on how Flagship’s newest fund could shape biotech’s future
https://endpts.com
-
Inspiring developments today from Flagship Pioneering with a $3.6 billion raise to drive groundbreaking innovations in health and sustainability. As part of the #FlagshipFounded ecosystem, we are pushing the boundaries of science to create a better future, together. On Bloomberg Television with Francine Lacqua, Noubar Afeyan, CEO and founder of Flagship Pioneering and our own chairman and co-founder, spoke about this new funding and its transformative potential. He highlighted our innovative approach, saying, “We can now computationally generate programmable antibodies to target any disease with unprecedented speed and precision.” Catch the full discussion to learn how we’re programming the future of medicine: https://lnkd.in/egcEgNrR #GenerativeAI | #ProteinEngineering | #NowWeCan
Flagship Pioneering Raises $3.6B for 'New Wave' of Health, AI Innovation
bloomberg.com
-
On July 11, our EVP and Head of Research and Development, Alexandra Snyder, MD, will be speaking at the "Oncology AI/ML - Proven Impact" panel during Leerink Partners AI/ML in Healthcare: Transformation or Evolution conference. As an oncologist who has witnessed the urgent need for better cancer treatments, Alex will discuss how leveraging technology and data allows us to craft therapies that target cancers at their core, offering new hope where traditional methods have fallen short. She will illustrate our commitment to delivering breakthrough therapies to patients who can't wait. Joining industry leaders Karim Beguir of InstaDeep, Ryan Richardson of BioNTech SE, and Iker Huerga of Tempus AI, with moderation by Daina Graybosch of Leerink Partners, Alex will provide insights on how these innovations are shaping the future of oncology. #PatientFirst | #GenerativeBiology
-
Our Computational Sciences team recently spent an exciting day at Fenway Park, enjoying a Boston Red Sox game together. This shared experience underscores the camaraderie and collaborative spirit that drive our groundbreaking innovations. Ready to push the boundaries of drug discovery with a team that’s redefining what’s possible? Apply now to join us as a Machine Learning Scientist and contribute to our mission of creating novel therapeutics at the intersection of computation and biology. Apply here: https://lnkd.in/gKaKkEGJ #GenerativeBiology | #UnapologeticallyScientific
-
Every Summer, #TeamGenerate takes a well-deserved week off over the Fourth of July to rest and recharge for what’s next. This break allows us to return with renewed energy and a fresh perspective, ready to continue pushing the boundaries of what’s possible. Accordingly, we will be closed next week and will be back on Monday, July 8. As one #FiercelyUnited organization, we’re looking forward to continuing to advance our vision of instantly generating optimal therapeutics for the greatest impact on human health. #AudaciouslyAmbitious I #UnapologeticallyScientific
-
In his talk at the AI-Science Workshop at the Simons Institute for the Theory of Computing of the University of California, Berkeley, our Head of Machine Learning John Ingraham explained how generative models such as Chroma are allowing us to expand the protein repertoire on Earth and enable the programmable generation of fit-for-purpose medicines. This work relies on highly interdisciplinary collaborations between computation, biology, and engineering, and we are just getting started. Watch the full talk below for more of the lessons we have learned along the way: https://lnkd.in/edWAr4Ts Are you an #ML scientist looking to create new paradigms for drug discovery? If that is you, apply here: https://lnkd.in/e-xd-Cvz #GenerativeBiology | #UnapologeticallyScientific
Illuminating protein space with generative models
https://www.youtube.com/
-
How does a late-night email turn into a biotech revolution? Lillian Eden for Massachusetts Institute of Technology shares how our CTO Gevorg Grigoryan, after hours of perfecting an email, reached out to Noubar Afeyan, Founder & CEO of Flagship Pioneering, in the wee hours of the morning with an idea to use data-driven protein design for therapeutic applications. Just 15 minutes later, he got a response that led to co-founding Generate:Biomedicines, revolutionizing protein design using #AI and blending biology, physics, and computational sciences. Fast forward nearly six years, and Gevorg says: “Now, we can just push a button and have a generative model spit out a new protein with close to perfect probability it will actually work.” Discover how together, #TeamGenerate is harnessing the power of data and #MachineLearning to program biology and dramatically improve the human condition. Read the full article to explore the breakthrough: https://lnkd.in/dRvnTRQx #NowWeCan | #ProteinEngineering |#GenerativeBiology
Alum Profile: Gevorg Grigoryan, PhD '07
https://biology.mit.edu
-
In 2024, women make up just 15.7% of the engineering workforce, highlighting the ongoing efforts required to achieve gender parity. Today, we celebrate International Women in Engineering Day, which aims to raise awareness about the underrepresentation of women in engineering and celebrate their achievements. This day is crucial for promoting gender equality and encouraging more women and girls to pursue careers in engineering. Engineering is integral for #TeamGenerate, from automation technology to data analysis and software engineering. We’re proud to spotlight some of the talented women engineers on our team, including Tharindi Hapuarachchi, PhD, Julia K., and Yiqing (Melody) Wang, who drive our mission forward every day. Join us in celebrating their achievements and the vital role women play in engineering. #WomenInSTEM | #WomenInEngineering | #INWED2024